Surrozen, Inc./DE Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Surrozen, Inc./DE stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $91.00K.
- Surrozen, Inc./DE stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $92.00K.
- Surrozen, Inc./DE stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $9.00K.
- Surrozen, Inc./DE stock issued during period, value, stock options exercised for the quarter ending 2023-09-30 was $3.00K.
- Surrozen, Inc./DE stock issued during period, value, stock options exercised for fiscal 2025 was $87.00K, a 123.08% increase from fiscal 2024.
- Surrozen, Inc./DE stock issued during period, value, stock options exercised for fiscal 2024 was $39.00K, a 1200.00% increase from fiscal 2023.
- Surrozen, Inc./DE stock issued during period, value, stock options exercised for fiscal 2023 was $3.00K.
- Surrozen, Inc./DE stock issued during period, value, stock options exercised for fiscal 2021 was $411.00K, a 146.11% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $91.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $92.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $87.00K 10-K · filed 2026-03-23 | |
| 2025-09-30 | $9.00K 10-Q · filed 2025-11-07 | |
| 2024-12-31 | $39.00K 10-K · filed 2026-03-23 | |
| 2023-12-31 | $3.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $3.00K 10-Q · filed 2024-11-06 | |
| 2021-12-31 | $411.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $72.00K 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $109.00K 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $196.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $167.00K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $14.00K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $8.00K 10-Q · filed 2021-11-15 | |
| 2020-03-31 | $84.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |